Hypersensitivity, pregnancy, breast-feeding, severe coronary artery disease and severe arrhythmia (solution for infusion).
Increases the risk of bleeding on the background of the introduction of heparin.
Low blood pressure, tachycardia, extrasystole.
Acute and chronic cerebral circulatory insufficiency: acute cerebral infarction, transient ischemia, progressive stroke, post-stroke condition, atherosclerosis of the cerebral arteries, post-traumatic and hypertensive encephalopathy, etc., symptoms of cerebral insufficiency (dizziness, headache, motor disorders, memory disorders, etc.), aphasia, changes in the retina and vascular membranes of the eye (atherosclerotic, angiospastic), degenerative processes in the yellow spot, secondary glaucoma associated with partial vascular thrombosis, hearing loss, Meniere's disease.
Increases blood supply to the brain and peripheral tissues, normalizes or lowers systemic blood pressure. Improves the trophism of eye tissues, the course of ophthalmic diseases with partial vascular thrombosis, inhibits the progression of deafness of vascular and toxic origin.
In a place protected from light, at a temperature not exceeding 25 °C.
Keep out of reach of children.
The shelf life of the drug Bradenton®2 года.Do not use after the expiration date indicated on the package.
Instructions for medical use Бравинтон® - инструкция по медицинскому применению - РУ № Р N000345/01 от 2008-10-131 tablet contains 0.005 g of vinpocetine, in a contour cell package of 10 pcs. , in a cardboard pack of 2 packages or in plastic bottles of 50 pcs., in a cardboard pack of 1 bottle.
1 ml of the infusion solution contains 5 mg of vinpocetine, in ampoules of 2 ml, in a contour cell package of 5 ampoules, in a cardboard pack of 2 packages.
Inside, 0.005-0.01 g 3 times a day for a long time. Course — at least 2 months. Improvement is usually observed after 1-2 weeks.
In/in, only in the form of a slow drip infusion. Initial dose of 20 mg/day in 500-1000 ml of infusion solution, then 30 mg/day in 500-1000 ml to 1 mg/kg/day (10-day with a gentle increase of the dose) for 10-14 days before giving injections, the dose is gradually reduced and transferred the patient to oral.
N06BX18 Vinpocetine
